ArticleOncoimmunology2020
A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1.
Article in Oncoimmunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Antigen-specific active immunotherapy for ovarian cancer.The Cochrane database of systematic reviews · 2018Pooled it
- The promise of immunotherapy in the treatment of sarcoma: A state-of-the-art review of practice changing research and future directions.Human vaccines & immunotherapeutics · 2026Review
- Integrative Spatial Transcriptomics and Immunoinformatics for Prognostic Multi-Epitope Vaccine Construct Prediction Against Synovial Sarcoma.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Vax-Innate: improving therapeutic cancer vaccines by modulating T cells and the tumour microenvironment.Nature reviews. Immunology · 2025Review
- Emerging immunotherapy and tumor microenvironment for advanced sarcoma: a comprehensive review.Frontiers in immunology · 2025Review
- NY-ESO-1 antigen: A promising frontier in cancer immunotherapy.Clinical and translational medicine · 2024Review
- Immune profiling of dedifferentiated liposarcoma and identification of novel antigens for targeted immunotherapy.Scientific reports · 2024Article
- Immune checkpoint inhibitors in sarcomas: a systematic review.Immuno-oncology technology · 2023Review
- Trial watch: chemotherapy-induced immunogenic cell death in oncology.Oncoimmunology · 2023Review
- New therapeutics for soft tissue sarcomas: Overview of current immunotherapy and future directions of soft tissue sarcomas.Frontiers in oncology · 2023Review
- Immunotherapy Plus Radiotherapy for the Treatment of Sarcomas: Is There a Potential for Synergism?OncoTargets and therapy · 2023Review
- DC-targeting lentivectors for cancer immunotherapy.Immunotherapy advances · 2023Review
- Kita-Kyushu Lung Cancer Antigen-1 (KK-LC-1): A Promising Cancer Testis Antigen.Aging and disease · 2022Review
- Lipid A analog CRX-527 conjugated to synthetic peptides enhances vaccination efficacy and tumor control.NPJ vaccines · 2022Article
- Exploring the landscape of immunotherapy approaches in sarcomas.Frontiers in oncology · 2022Review
- Immunotherapy in soft tissue and bone sarcoma: unraveling the barriers to effectiveness.Theranostics · 2022Review
- Targeting cancer testis antigens in synovial sarcoma.Journal for immunotherapy of cancer · 2021Review
- Establishment and characterization of NCC-SS4-C1: a novel patient-derived cell line of synovial sarcoma.Human cell · 2021Article
- Assessment of Image-Guided Intratumoral Delivery of Immunotherapeutics in Patients With Cancer.JAMA network open · 2020Article
- Modulating the immune system through nanotechnology.Seminars in immunology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 14 institutions in 3 countries.
Funding
Abstract
Preclinical data suggest that a "prime-boost" vaccine regimen using a target-expressing lentiviral vector for priming, followed by a recombinant protein boost, may be effective against cancer; however, this strategy has not been evaluated in a clinical setting. CMB305 is a prime-boost vaccine designed to induce a broad anti-NY-ESO-1 immune response. It is composed of LV305, which is an NY-ESO-1 expressing lentiviral vector, and G305, a recombinant adjuvanted NY-ESO-1 protein. This multicenter phase 1b, first-in-human trial evaluated CMB305 in patients with NY-ESO-1 expressing solid tumors. Safety was examined in a 3 + 3 dose-escalation design, followed by an expansion with CMB305 alone or in a combination with either oral metronomic cyclophosphamide or intratumoral injections of a toll-like receptor agonist (glucopyranosyl lipid A). Of the 79 patients who enrolled, 81.0% had sarcomas, 86.1% had metastatic disease, and 57.0% had progressive disease at study entry. The most common adverse events were fatigue (34.2%), nausea (26.6%), and injection-site pain (24.1%). In patients with soft tissue sarcomas, a disease control rate of 61.9% and an overall survival of 26.2 months (95% CI, 22.1-NA) were observed. CMB305 induced anti-NY-ESO-1 antibody and T-cell responses in 62.9% and 47.4% of patients, respectively. This is the first trial to test a prime-boost vaccine regimen in patients with advanced cancer. This approach is feasible, can be delivered safely, and with evidence of immune response as well as suggestion of clinical benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.